Price Action Don’t Lie: NxStage Medical, Inc. Can’t Be More Safe. Trades Significantly Higher

Price Action Don't Lie: NxStage Medical, Inc. Can't Be More Safe. Trades Significantly Higher

The stock of NxStage Medical, Inc. (NASDAQ:NXTM) is a huge mover today! About 1.39 million shares traded hands or 277.16% up from the average. NxStage Medical, Inc. (NASDAQ:NXTM) has risen 38.82% since April 1, 2016 and is uptrending. It has outperformed by 37.61% the S&P500.
The move comes after 9 months positive chart setup for the $1.44B company. It was reported on Nov, 3 by Barchart.com. We have $33.89 PT which if reached, will make NASDAQ:NXTM worth $619.20 million more.

NxStage Medical, Inc. (NASDAQ:NXTM) Ratings Coverage

Out of 6 analysts covering NxStage Medical (NASDAQ:NXTM), 5 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 83% are positive. NxStage Medical has been the topic of 7 analyst reports since November 4, 2015 according to StockzIntelligence Inc. As per Friday, December 11, the company rating was initiated by Sterne Agee CRT. The firm has “Buy” rating by BTIG Research given on Friday, December 18. Northland Capital upgraded the stock to “Outperform” rating in Tuesday, June 28 report. The firm has “Overweight” rating given on Thursday, March 31 by Piper Jaffray. The stock of NxStage Medical, Inc. (NASDAQ:NXTM) earned “Buy” rating by Canaccord Genuity on Tuesday, August 2.

According to Zacks Investment Research, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.”

Insitutional Activity: The institutional sentiment decreased to 0.97 in 2016 Q2. Its down 0.37, from 1.34 in 2016Q1. The ratio dropped, as 22 funds sold all NxStage Medical, Inc. shares owned while 45 reduced positions. 26 funds bought stakes while 39 increased positions. They now own 61.50 million shares or 4.11% more from 59.07 million shares in 2016Q1.
State Street holds 0% or 1.04M shares in its portfolio. Altrinsic Glob Advsrs Limited has invested 0.38% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Rs Invest Mgmt Ltd Limited Liability Company has 2.15M shares for 0.48% of their US portfolio. First Light Asset Management Ltd Liability accumulated 2.55% or 254,113 shares. Bank & Trust Of New York Mellon has invested 0% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Moreover, Glenmede Trust Co Na has 0% invested in NxStage Medical, Inc. (NASDAQ:NXTM) for 1 shares. Mackenzie has 0% invested in the company for 38,969 shares. National Bank Of Montreal Can has 0.02% invested in the company for 687,791 shares. Delta Lloyd Nv reported 175,000 shares or 0.13% of all its holdings. Schwab Charles Inv last reported 460,272 shares in the company. Grandeur Peak Global Advsrs Ltd Liability Company has 73,600 shares for 0.22% of their US portfolio. The Wisconsin-based Broadview Advisors Lc has invested 1.95% in NxStage Medical, Inc. (NASDAQ:NXTM). Paloma Partners Mgmt has invested 0.01% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Blair William And Il has invested 0.18% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Pura Vida Investments Lc, a New York-based fund reported 200,000 shares.

Insider Transactions: Since May 10, 2016, the stock had 0 insider purchases, and 3 selling transactions for $115,791 net activity. $19,026 worth of NxStage Medical, Inc. (NASDAQ:NXTM) was sold by Turk Joseph E Jr on Tuesday, May 10. $69,930 worth of NxStage Medical, Inc. (NASDAQ:NXTM) was sold by MOORE CRAIG W.

More notable recent NxStage Medical, Inc. (NASDAQ:NXTM) news were published by: Fool.com which released: “Here’s Why NxStage Medical, Inc.’s Stock Is Popping Today” on November 03, 2016, also Fool.com with their article: “Home and Critical Care Drive NxStage Medical, Inc. Q2 Improvement” published on August 04, 2016, Fool.com published: “Why NxStage Medical, Inc. Guided Lower Today” on February 10, 2016. More interesting news about NxStage Medical, Inc. (NASDAQ:NXTM) were released by: Prnewswire.com and their article: “NxStage Announces Publication of Journal Supplement with Major Clinical …” published on October 25, 2016 as well as Prnewswire.com‘s news article titled: “NxStage Highlights Innovative Nx2me Platform Data at Partners HealthCare …” with publication date: October 21, 2016.

NXTM Company Profile

NxStage Medical, Inc., incorporated on October 20, 1998, is a medical technology company. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. The Firm operates through three divisions: System One, In-Center and Services. The Firm offers its services and products to various markets, such as home, critical care and in-center. The Company’s primary product, the System One, delivers the therapeutic flexibility and clinical benefits associated with dialysis machines that can be used by healthcare professionals and trained lay users alike in various settings, including patient homes, as well as traditional care settings, such as hospitals and dialysis centers. The Firm operates NxStage Kidney Care dialysis centers that treat end-stage renal disease patients directly.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment